Our research on the mechanism of PSORI-CM01 in treating psoriasis vulgaris in vivo and in vitro suggests that PSORI-CM01 may improve psoriatic lesions by inhibiting Krt6 dependent of miR-31. This evidence concerns the gene KRT72 and psoriasis vulgaris.